A Shot in the Arm: Intercell's Vaccine for Japanese Encephalitis Wins ACIP Nod
This article was originally published in The Pink Sheet Daily
The vaccine maker clears a key hurdle to market a product that will likely find widening appeal as travel to Asia intensifies.
You may also be interested in...
First vaccine approval for Intercell in US brings a new player fully into the vaccine business; Austrian company has key partnerships pending with Merck, Novartis and Sanofi.
Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.
Over the past few years, frustrating instances of shortages and recalls – particularly generics – have been blamed on inferior quality control at countless suppliers of active pharmaceutical ingredients and finished products, especially those based in India and China.